Genomewide association study identifies GALC as susceptibility gene for mucous membrane pemphigoid

Christian D Sadik1, Julia Bischof2, Nina van Beek1

  • 1Department of Dermatology, Allergy, and Venereology, University of Lübeck, Lübeck, Germany.

Experimental Dermatology
|November 15, 2017
PubMed

Insights

Genetic factors contribute to mucous membrane pemphigoid (MMP) risk. This study identified specific gene variants in GALC and between CASC16 and CHD9 associated with MMP susceptibility in a British cohort.

Area of Science:

  • Genetics
  • Immunology
  • Dermatology

Background:

  • Mucous membrane pemphigoid (MMP) is a rare, autoimmune blistering disease with poorly understood pathogenesis.
  • Genetic predispositions beyond HLA class II alleles are largely unknown in MMP.

Purpose of the Study:

  • To identify novel susceptibility genes for MMP in a British patient cohort.
  • To investigate the genetic basis of MMP beyond known associations.

Main Methods:

  • Genome-wide association study (GWAS) in 106 British MMP patients.
  • Utilized UK Blood Service and 1958 British Birth Cohort as controls.
  • Replicated findings in a German cohort of 42 MMP patients.

Main Results:

  • Identified 38 significant single nucleotide polymorphisms (SNPs) in 28 haploblocks.
  • Confirmed association of MMP with SNPs in GALC (rs17203398, OR: 3.9).
  • Confirmed association with recessive polymorphisms between CASC16 and CHD9 (rs9936045, OR: 3.1).

Conclusions:

  • Genetic factors partially determine MMP risk.
  • SNPs in GALC suggest a role for β-galactocerebrosidase in MMP pathogenesis.
  • Intergenic polymorphisms between CASC16 and CHD9 may influence nearby gene activity, contributing to MMP development.

Related Concept Videos

Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
15.8K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
20
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
19